Elimination of Tumor Suppressor Proteins during Liver Carcinogenesis
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2014, Vol 1, Issue 1
Abstract
Liver cancer is one of the most lethal cancers. Quiescent liver expresses up to 20 tumor suppressor proteins including Rb, p53, CCAAT-Enhancer-Binding Protein (C/EBP)α, Hepatocyte Nuclear Factor (HNF4)α and p16 and it is well protected from development of liver cancer. However, the negative control of liver proliferation by these factors and other tumor suppressor genes is eliminated in liver cancer. Studies of liver regeneration after surgery and injury have provided fundamental mechanisms on how liver neutralizes tumor suppressor proteins for the time of regeneration; however, studies of liver cancer in animal models and in human samples showed several additional pathways of this neutralization. One of these additional pathways includes activation of a small subunit of the proteasome, Gankyrin. Gankyrin is dramatically increased in human hepatocellular carcinoma (HCC) and in animal models of carcinogenesis. Once activated Gankyrin triggers degradation of main tumor suppressor proteins during development of liver cancer using slightly different mechanisms. Recent studies identified mechanisms which repress Gankyrin in quiescent livers and mechanisms of activation of Gankyrin in liver cancer. These mechanisms involve a communication between Farnesoid X Receptor (FXR) signaling and chromatin remodelling proteins mediated by members of C/EBP family. It has been recently shown that C/EBPα plays a critical role in this network and that the activation of C/EBPα in cirrhotic livers with HCC inhibits cancer progression. This C/EBPαdependent inhibition of liver cancer involves activation of a majority of tumor suppressor genes and repression of tumor initiating pathways such as β-catenin and c-myc. These recent findings provide a background for FXR-based and C/EBPα-based approaches to treat liver cancer.
Authors and Affiliations
Nikolai A. Timchenko
Keywords
Related Articles
- EP ID EP552522
- DOI 10.17140/CSMMOJ-1-104
- Views 123
- Downloads 0
Rounding Down Chemotherapeutic Agents to the Nearest Vial Size as a Cost Containment Measure
Background: High cancer treatment costs significantly affect health care expenditures. Drug waste reduction of costly drugs can reduce the treatment cost. Methods: A retrospective study conducted at King Abdulaziz Medica...
The Emerging Spectrum of Early Life Exposure-Related Inflammation and Epigenetic Therapy
Early life exposure to a variety of insults during sensitive windows of development can reprogram normal physiological responses and alter disease susceptibility later in life. During this process, inflammation triggered...
Knowledge of the Molecular Signaling Pathways Improves the Chances of Treatment of Gastrointestinal Stromal Tumors
Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal (nonepithelial) tumors of the gastrointestinal tract. A better molecular understanding of this entity, as Christopher L. Cordless in Modern Patholog...
Dysadherin: A Novel Oncogenic Molecular Biomarker in Oesophageal Cancer
Dysadherin or FXYD5 is a transmembrane glycoprotein, identified for the first time in 2002 by a team of Japanese researchers.1 Although, it is generally accepted that most of its action is derived from the increased maxi...
Is it Time to Start Using Mitochondrial DNA Copy Number as an Indicator of Health and Diseases?
Clinical biochemistry and pathology have contributed too many assays for diagnosis and prognosis of human health and diseases. Bedside biochemistry has revolutionized modern medicine and the invention of new generation b...